Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
Heuser M, Smith BD, Fiedler W, Sekeres MA, Montesinos P, Leber B, Merchant A, Papayannidis C, Pérez-Simón JA, Hoang CJ, O'Brien T, Ma WW, Zeremski M, O'Connell A, Chan G, Cortes JE. Heuser M, et al. Among authors: hoang cj. Ann Hematol. 2021 May;100(5):1181-1194. doi: 10.1007/s00277-021-04465-4. Epub 2021 Mar 19. Ann Hematol. 2021. PMID: 33740113 Free PMC article. Clinical Trial.
A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy.
Solem CT, Bell TJ, Kwon Y, Cappelleri JC, Johnson C, Bhattacharyya H, Hoang CJ, Cortes JE. Solem CT, et al. Among authors: hoang cj. Cancer. 2020 Oct 1;126(19):4315-4321. doi: 10.1002/cncr.33072. Epub 2020 Jul 22. Cancer. 2020. PMID: 32697335 Free PMC article. Clinical Trial.
Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
Heuser M, Smith BD, Fiedler W, Sekeres MA, Montesinos P, Leber B, Merchant A, Papayannidis C, Pérez-Simón JA, Hoang CJ, O'Brien T, Ma WW, Zeremski M, O'Connell A, Chan G, Cortes JE. Heuser M, et al. Among authors: hoang cj. Ann Hematol. 2021 Jul;100(7):1917-1918. doi: 10.1007/s00277-021-04545-5. Ann Hematol. 2021. PMID: 33978823 Free PMC article. No abstract available.
Veno-occlusive disease risk in pediatric patients with acute myeloid leukemia treated with gemtuzumab ozogamicin before allogeneic hematopoietic cell transplantation.
Duncan C, St Martin A, Pérez WS, Steinert P, Zhang MJ, Chirnomas D, Hoang CJ, Loberiza FR Jr, Saber W. Duncan C, et al. Among authors: hoang cj. Pediatr Blood Cancer. 2021 Aug;68(8):e29067. doi: 10.1002/pbc.29067. Epub 2021 Apr 19. Pediatr Blood Cancer. 2021. PMID: 33871892 Free PMC article.
Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.
Ho VT, Martin AS, Pérez WS, Steinert P, Zhang MJ, Chirnomas D, Hoang CJ, Loberiza FR Jr, Saber W. Ho VT, et al. Among authors: hoang cj. Biol Blood Marrow Transplant. 2020 May;26(5):884-892. doi: 10.1016/j.bbmt.2019.12.763. Epub 2019 Dec 28. Biol Blood Marrow Transplant. 2020. PMID: 31891815 Free PMC article.
14 results